New COVID-19 Test Uses Magnetic Beads to Detect SARS-CoV-2 Virus
|
By HospiMedica International staff writers Posted on 12 Oct 2020 |

Image: New COVID-19 Test Uses Magnetic Beads to Detect SARS-CoV-2 Virus (Photo courtesy of NTNU)
A highly sensitive COVID-19 test, developed by researchers at the Norwegian University of Science and Technology (NTNU Trondheim, Norway), relies on magnetic nanoparticles to extract viral RNA.
A key aspect of this made-in-Norway COVID-19 test is a specific combination of polar solvents, buffers, salts and other chemicals that do not damage the viral RNA molecule itself. The solution contains substances that crack the virus open so that its genetic material can be extracted. NTNU has also developed iron oxide magnetic nanoparticles that strongly bind RNA. Once the magnetic nanoparticles are coated with the viral RNA, they can be removed from the solution using a magnet. PCR technology can then identify the genetic code from the RNA and compare it to the coronavirus.
The newly developed manufacturing process has proved to be very upscalable, which has enabled the NTNU labs to produce these high-quality and high-performance magnetic nanoparticles in very high volumes. Three laboratories at the Department of Chemical Engineering are currently manufacturing the magnetic nanoparticles, while another laboratory at the Department of Clinical and Molecular Medicine is making the solvents and buffers. At the same time, the test kits are subject to rigorous quality control and validation before shipping to customers. The magnetic nanobeads and buffers, and then the entire test kits are verified against a known COVID-19 positive patient sample.
In the process of gearing up to produce tests for Norway, the researchers improved the efficiency of the production system to the point where the lab is able to make more than enough tests for use in Norway. NTNU produces up to 1.2 million test kits per week and increases in production capacity will allow the groups to produce up to five million test kits a week. NTNU has signed agreements to deliver as many as one million COVID-19 test kits to DTU, the Technical University of Denmark, and APS LABS, an Indian biotech company. More than five million NTNU COVID-19 tests have already been supplied to the Norwegian health authorities. NTNU Technology Transfer has filed patent applications on the methods and products related to the NTNU COVID-19 test. The motivation is to secure control of the intellectual rights and provide access to the new test in an ethical and justifiable manner. At the same time, the university hopes to expand the number of countries to which the test will be exported.
“Testing and infection tracking are absolutely essential to maintaining control of the infection situation. The fact that NTNU has developed a new test method for detecting the coronavirus means that more people can be tested and that patients can get answers faster. It is very positive that this technology can now also be useful internationally,” said Bent Høie, Norway’s Minister of Health and Care Services.
Related Links:
Norwegian University of Science and Technology
A key aspect of this made-in-Norway COVID-19 test is a specific combination of polar solvents, buffers, salts and other chemicals that do not damage the viral RNA molecule itself. The solution contains substances that crack the virus open so that its genetic material can be extracted. NTNU has also developed iron oxide magnetic nanoparticles that strongly bind RNA. Once the magnetic nanoparticles are coated with the viral RNA, they can be removed from the solution using a magnet. PCR technology can then identify the genetic code from the RNA and compare it to the coronavirus.
The newly developed manufacturing process has proved to be very upscalable, which has enabled the NTNU labs to produce these high-quality and high-performance magnetic nanoparticles in very high volumes. Three laboratories at the Department of Chemical Engineering are currently manufacturing the magnetic nanoparticles, while another laboratory at the Department of Clinical and Molecular Medicine is making the solvents and buffers. At the same time, the test kits are subject to rigorous quality control and validation before shipping to customers. The magnetic nanobeads and buffers, and then the entire test kits are verified against a known COVID-19 positive patient sample.
In the process of gearing up to produce tests for Norway, the researchers improved the efficiency of the production system to the point where the lab is able to make more than enough tests for use in Norway. NTNU produces up to 1.2 million test kits per week and increases in production capacity will allow the groups to produce up to five million test kits a week. NTNU has signed agreements to deliver as many as one million COVID-19 test kits to DTU, the Technical University of Denmark, and APS LABS, an Indian biotech company. More than five million NTNU COVID-19 tests have already been supplied to the Norwegian health authorities. NTNU Technology Transfer has filed patent applications on the methods and products related to the NTNU COVID-19 test. The motivation is to secure control of the intellectual rights and provide access to the new test in an ethical and justifiable manner. At the same time, the university hopes to expand the number of countries to which the test will be exported.
“Testing and infection tracking are absolutely essential to maintaining control of the infection situation. The fact that NTNU has developed a new test method for detecting the coronavirus means that more people can be tested and that patients can get answers faster. It is very positive that this technology can now also be useful internationally,” said Bent Høie, Norway’s Minister of Health and Care Services.
Related Links:
Norwegian University of Science and Technology
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read more
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read moreSurgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel








